Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer

Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer

BackgroundTissue biopsy is an integral part of the diagnostic approach to lung cancer. It is however invasive and limited by heterogeneity. Liquid biopsies may complement tissue testing by providing additional molecular information and may be particularly helpful in patients from whom obtaining suff...

Full description

Bibliographic Details
Main Authors:	Yukti Choudhury, Min-Han Tan, Jun Li Shi, Augustine Tee, Kao Chin Ngeow, Jonathan Poh, Ruth Rosalyn Goh, Jamie Mong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Medicine
Subjects:	liquid biopsy and circulating tumor DNA non-small cell lung cancer (NSCLC) plasma-first next generation sequencing amplicon-based NGS tumor heterogeneity
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.758464/full

Similar Items

Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients
by: Ana Barbosa, et al.
Published: (2021-09-01)

Circulating Tumor DNA Characteristics Based on Next Generation Sequencing and Its Correlation With Clinical Parameters in Patients With Lymphoma
by: Xiao-Bo Wu, et al.
Published: (2022-07-01)

Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
by: Andrew B Gill, et al.
Published: (2020-11-01)

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection
by: Andi K. Cani, et al.
Published: (2022-05-01)

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer
by: Aleksandra Bożyk, et al.
Published: (2022-10-01)

Performance of the Oncomine<sup>TM</sup> Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice
by: Giuseppa De Luca, et al.
Published: (2020-04-01)

Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer
by: Hye-Yeon Ju, et al.
Published: (2022-05-01)

Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer
by: Jucimara Colombo, et al.
Published: (2021-10-01)

Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?
by: Elisabetta Rossi, et al.
Published: (2019-10-01)

Improvements in Quality Control and Library Preparation for Targeted Sequencing Allowed Detection of Potentially Pathogenic Alterations in Circulating Cell-Free DNA Derived from Plasma of Brain Tumor Patients
by: Paulina Szadkowska, et al.
Published: (2022-08-01)

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer
by: John Jiang, et al.
Published: (2020-09-01)

Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue
by: Tania Rossi, et al.
Published: (2021-09-01)

Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
by: Hiu Ting Chan, et al.
Published: (2020-08-01)

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
by: Stephanie J. Yaung, et al.
Published: (2022-04-01)

Circulating tumor DNA detection (liquid biopsy): prospects in oncology
by: N. V. Zhukov, et al.
Published: (2015-01-01)

Circulating tumor DNA detection (liquid biopsy): prospects in oncology
by: N. V. Zhukov, et al.
Published: (2015-01-01)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
by: Marco Russano, et al.
Published: (2020-05-01)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
by: Balendran-Braun S, et al.
Published: (2021-08-01)

Post-Surgery Circulating Tumor Cells and <i>AXL</i> Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma
by: Diego de Miguel-Pérez, et al.
Published: (2019-11-01)

Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer
by: Esther Visser, et al.
Published: (2023-01-01)

Development of an Amplicon-Based Next-Generation Sequencing Protocol to Identify Leishmania Species and Other Trypanosomatids in Leishmaniasis Endemic Areas
by: Luz H. Patiño, et al.
Published: (2021-10-01)

Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer
by: Hai‐Ming Huang, et al.
Published: (2021-02-01)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01)

Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
by: Hestia Mellert, et al.
Published: (2021-01-01)

Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients
by: Natalia Galant, et al.
Published: (2024-02-01)

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
by: Jianjiang Xie, et al.
Published: (2023-03-01)

Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
by: Oddmund Nordgård, et al.
Published: (2021-04-01)

CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor
by: Jacqueline Aparecida Torres, et al.
Published: (2023-07-01)

Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
by: Filip Ionescu, et al.
Published: (2022-03-01)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
by: Simon Heeke, et al.
Published: (2021-04-01)

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
by: Aliki Ntzifa, et al.
Published: (2021-11-01)

The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor
by: Chen Y, et al.
Published: (2017-12-01)

Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma
by: Suman Verma, et al.
Published: (2020-10-01)

Optical nanomaterial-based detection of biomarkers in liquid biopsy
by: Young Jun Kim, et al.
Published: (2024-03-01)

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature
by: Yolcar Chamorro, et al.
Published: (2022-12-01)

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients
by: Corinna Keup, et al.
Published: (2020-04-01)

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
by: Loc Carlo Bao, et al.
Published: (2024-03-01)

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression
by: Marzia Del Re, et al.
Published: (2024-03-01)

Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
by: Elisabetta Zulato, et al.
Published: (2021-08-01)

The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non‐small cell lung cancer
by: Martin Metzenmacher, et al.
Published: (2022-08-01)